Drug Delivery Devices for Inhaled Medicines

Lexmond, Anne J.; Forbes, Ben

doi:10.1007/164_2016_67

Cited by 16 publications

(11 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Features of pulmonary physiology, such as a large surface area, a thin alveolar-blood barrier, along with the combined advantages of low enzymatic activity and first-pass metabolism, present the possibility of attaining high bioavailability when aerosolized drugs are delivered via the lungs [12]. The primary aim of inhalational aerosol therapy is to deliver high concentrations of drugs either directly to lung tissue to target respiratory diseases [13] or via the lungs as a route to target systemic diseases, such as cancer or diabetes [14,15]. Directly targeted pulmonary drug delivery has crucial benefits over systemic administration, such as more rapid onset of action, increased therapeutic effects, and reduced systemic side effects, as the required lung dosage can be achieved with lower doses as well as the opportunity to repurpose existing drugs [16] leading to increased interest in the field of aerosolized drug therapy in intensive care units (ICU).…”

Section: Introductionmentioning

confidence: 99%

Future Trends in Nebulized Therapies for Pulmonary Disease

McCarthy

González

Higgins

2020

JPM

View full text Add to dashboard Cite

Aerosol therapy is a key modality for drug delivery to the lungs of respiratory disease patients. Aerosol therapy improves therapeutic effects by directly targeting diseased lung regions for rapid onset of action, requiring smaller doses than oral or intravenous delivery and minimizing systemic side effects. In order to optimize treatment of critically ill patients, the efficacy of aerosol therapy depends on lung morphology, breathing patterns, aerosol droplet characteristics, disease, mechanical ventilation, pharmacokinetics, and the pharmacodynamics of cell-drug interactions. While aerosol characteristics are influenced by drug formulations and device mechanisms, most other factors are reliant on individual patient variables. This has led to increased efforts towards more personalized therapeutic approaches to optimize pulmonary drug delivery and improve selection of effective drug types for individual patients. Vibrating mesh nebulizers (VMN) are the dominant device in clinical trials involving mechanical ventilation and emerging drugs. In this review, we consider the use of VMN during mechanical ventilation in intensive care units. We aim to link VMN fundamentals to applications in mechanically ventilated patients and look to the future use of VMN in emerging personalized therapeutic drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

Future Trends in Nebulized Therapies for Pulmonary Disease

McCarthy

González

Higgins

2020

JPM

View full text Add to dashboard Cite

show abstract

“…Local administration is an elegant solution to the problem of a narrow therapeutic window. For respiratory diseases affecting the lungs, inhaler- or nebulizer-administered therapies represent a safe and efficient means of delivering drug to the active site [16]. Many well-characterized technologies are already available for drug inhalation, and some antiviral drugs are already administered through this route [17].…”

Section: Introductionmentioning

confidence: 99%

Using translational in vitro-in vivo modeling to improve drug repurposing outcomes for inhaled COVID-19 therapeutics

Stoddard¹,

Yuan²,

Chakravarty³

2021

Preprint

View full text Add to dashboard Cite

The ongoing COVID-19 pandemic has created an urgent need for antiviral treatments that can be deployed rapidly. Drug repurposing represents a promising means of achieving this objective, but repurposing efforts are often unsuccessful. A common hurdle to effective drug repurposing is a failure to achieve a sufficient therapeutic window in the new indication. A clear example is the use of ivermectin in COVID-19, where the approved dose (administered orally) fails to achieve therapeutic concentrations in the lungs. Our proposed solution to the problem of ineffective drug repurposing for COVID-19 antivirals is two-fold: to broaden the therapeutic window by reformulating therapeutics for the pulmonary route, and to select drug repurposing candidates based on their model-predicted therapeutic index for inhalation. In this article, we propose a two-stage model-driven screening and validation process for selecting inhaled antiviral drug repurposing candidates. While we have applied this approach in the specific context of COVID-19, this in vitro-in vivo translational methodology is also broadly applicable to repurposing drugs for diseases of the lower respiratory tract.

show abstract

“…(<0,5 мкм) відкладаються на стінках дихальних шляхів унаслідок дифузії. Слід зауважити, що частинки такого розміру частіше виштовхуються з видихом, аніж відкладаються в респіраторному тракті [11].…”

unclassified

“…От же, не с лід початково припускати сумісність препарату та небулайзера [11]. Запропоновано навіть уживати термін «небулайзерна система», котрий підкреслює необхідність сумісності небулайзера та препарату для досягнення оптимальної доставки аерозолю до легень.…”

unclassified

“…Аеродинамічний діаметр частинки -це діаметр сфери в аерозолі певної щільності, що осідає в нерухомому повітрі (тобто під впливом сили тяжіння) з такою самою швидкістю, як і ця частинка. Частинки з аналогічним аеродинамічним діаметром демонструють однакову інерційну поведінку [11].…”

unclassified

See 1 more Smart Citation

Investigation of the distribution of particles of drugs with the help of cascade impactor

Dobrianskyi¹,

Holyshkin²,

Los³

et al. 2020

View full text Add to dashboard Cite

BACKGROUND. Successful nebulization is a result of joint usage of nebulizer and medication, which equally define availability and disposition of the active substance. Amount of the substance delivered by different nebulizer systems may differ in more than 10 times. OBJECTIVE. The aim of the study was to investigate the distribution of aerosol particles of drugs for inhalation manufactured by «Yuria-Pharm» under conditions of usage of Ulaizer Home. MATERIALS AND METHODS. We investigated Ulaizer Home nebulizer and medications for inhalation (Decasan, Lorde hyal, Nebufluson, Nebutamol) with the help of new generation impactor (“Copley Scientific Limited”, Great Britain). RESULTS AND DISCUSSION. Mass median aerodynamic diameter (MMAD) of Decasan particles was 4.878 µm, geometric standard deviation (GSD) – 1.72. MMAD of Lorde hyal particles was 3.194 µm, GSD – 1.556. Drop distribution for Nebutamol was alike the distribution for non-viscous aqueous solutions (MMAD – 5.363 µm, GSD – 1.924). For Nebufluson MMAD was 5.491 µm, GSD – 1.724. CONCLUSIONS. The delivery of the inhaled drug to the required area of the respiratory system is a key to successful nebulization. It directly depends on the parameters of the aerosol. The distribution of particles of drugs manufactured by «Yuria-Pharm» in case of nebulization using Ulaizer Home allows to deliver the required amount of drug to the predefined parts of the respiratory system.

show abstract

Drug Delivery Devices for Inhaled Medicines

Cited by 16 publications

References 76 publications

Future Trends in Nebulized Therapies for Pulmonary Disease

Future Trends in Nebulized Therapies for Pulmonary Disease

Using translational in vitro-in vivo modeling to improve drug repurposing outcomes for inhaled COVID-19 therapeutics

Investigation of the distribution of particles of drugs with the help of cascade impactor

Contact Info

Product

Resources

About